Amedeo Smart

Free Medical Literature Service

 

Amedeo

Prostate Cancer
  Free Subscription

Articles published in
Cancer Res
    October 2025
  1. ALHOURANI F, Tauziet M, Ayeul M, Dambrun P, et al
    Targeting SUV4-20H Epigenetic Enzymes Enhances Topoisomerase II Poisoning in Prostate Cancer.
    Cancer Res. 2025 Oct 1. doi: 10.1158/0008-5472.CAN-24-3974.
    >> Share

    September 2025
  2. LIU S, Hsu EC, Aslan M, Garcia-Marques F, et al
    Extracellular Domain Shedding of TROP2 Activates EGFR Signaling to Drive Prostate Cancer Metastasis.
    Cancer Res. 2025 Sep 5. doi: 10.1158/0008-5472.CAN-24-4855.
    >> Share

  3. MURPHY KC, DeMarco KD, Zhou L, Peura J, et al
    MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T Cell and Immunotherapy Responses in Prostate Cancer.
    Cancer Res. 2025 Sep 3. doi: 10.1158/0008-5472.CAN-25-2532.
    >> Share

  4. JIANG J, Liu S, Xu C, He L, et al
    LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer.
    Cancer Res. 2025 Sep 3. doi: 10.1158/0008-5472.CAN-25-0587.
    >> Share

    August 2025
  5. GUO X, Zhong J, Qian J, Pan X, et al
    tRF-21LeuTAA Promotes Oxidative Stress by Altering Glutathione Metabolic Enzymes to Support Prostate Cancer Progression.
    Cancer Res. 2025 Aug 29. doi: 10.1158/0008-5472.CAN-25-0273.
    >> Share

  6. DAI Y, Liu L, Luo Y, Zhang C, et al
    Malonyl-CoA Promotes Prostate Cancer Progression and Castration Resistance by Enhancing Lipogenesis and Ran Activation.
    Cancer Res. 2025 Aug 27. doi: 10.1158/0008-5472.CAN-24-4247.
    >> Share

  7. VENKADAKRISHNAN VB, Presser A, Voss NCE, Neiswender J, et al
    Epigenetic De-repression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression.
    Cancer Res. 2025 Aug 21. doi: 10.1158/0008-5472.CAN-25-0636.
    >> Share

  8. HOSSEINI N, Mannan R, Rebernick RJ, Su F, et al
    Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration Resistant Prostate Cancer.
    Cancer Res. 2025 Aug 18. doi: 10.1158/0008-5472.CAN-24-3687.
    >> Share

  9. CORDOVA RA, Elbanna M, Rupert C, Orsi SA, et al
    Caloric Restriction Enhances the Efficacy of Anti-Androgen Therapy in Prostate Cancer by Inhibiting Androgen Receptor Translation.
    Cancer Res. 2025 Aug 8. doi: 10.1158/0008-5472.CAN-24-1986.
    >> Share

  10. MA S, Ge Y, Lu Z, Zhang J, et al
    Integrated Omics and Multi-Cohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer.
    Cancer Res. 2025 Aug 4. doi: 10.1158/0008-5472.CAN-24-5018.
    >> Share

    July 2025
  11. YE Q, Ma B, Li L, Wang Z, et al
    A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition.
    Cancer Res. 2025 Jul 29. doi: 10.1158/0008-5472.CAN-24-4096.
    >> Share

  12. ZHANG J, Chen W, Zhang C, He Q, et al
    Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion.
    Cancer Res. 2025 Jul 23. doi: 10.1158/0008-5472.CAN-24-3748.
    >> Share

    April 2025
  13. SMELIK M, Diaz-Roncero Gonzalez D, An X, Heer R, et al
    Combining Spatial Transcriptomics, Pseudotime, and Machine Learning Enables Discovery of Biomarkers for Prostate Cancer.
    Cancer Res. 2025 Apr 28. doi: 10.1158/0008-5472.CAN-25-0269.
    >> Share

  14. CRUZ-HERNANDEZ CD, Smith B, Billet S, Thiruvalluvan M, et al
    A Cyanobacteria-derived RNA aptamer resensitizes prostate cancer to hormone therapy.
    Cancer Res. 2025 Apr 28. doi: 10.1158/0008-5472.CAN-24-4039.
    >> Share

    February 2025
  15. ZHAO Y, Ramesh N, Xu P, Sei E, et al
    Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer During Serial Therapy.
    Cancer Res. 2025 Feb 24. doi: 10.1158/0008-5472.CAN-24-1943.
    >> Share

  16. ZHANG C, Ding J, Lim KS, Zhou W, et al
    JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer.
    Cancer Res. 2025 Feb 4. doi: 10.1158/0008-5472.CAN-23-2796.
    >> Share

    December 2024
  17. SIPOLA J, Munzur AD, Kwan EM, Seo CCY, et al
    Plasma cell-free DNA chromatin immunoprecipitation profiling depicts phenotypic and clinical heterogeneity in advanced prostate cancer.
    Cancer Res. 2024 Dec 9. doi: 10.1158/0008-5472.CAN-24-2052.
    >> Share

    November 2024
  18. BAE TH, Sung KW, Pham TM, Najy AJ, et al
    An Autophagy-Targeting Chimera Induces Degradation of Androgen Receptor Mutants and AR-v7 in Castration-Resistant Prostate Cancer.
    Cancer Res. 2024 Nov 12. doi: 10.1158/0008-5472.CAN-24-0591.
    >> Share

  19. MCQUILLEN CN, Brady NJ
    ASCL1 Drives the Development of Neuroendocrine Prostate Cancer.
    Cancer Res. 2024;84:3499-3501.
    >> Share

    October 2024
  20. ZHANG L, Troccoli CI, Mateo-Victoriano B, Misiara Lincheta L, et al
    Stimulating Soluble Guanylyl Cyclase with the Clinical Agonist Riociguat Restrains the Development and Progression of Castration-Resistant Prostate Cancer.
    Cancer Res. 2024 Oct 10. doi: 10.1158/0008-5472.CAN-24-0133.
    >> Share

    September 2024
  21. RODARTE KE, Nir Heyman S, Guo L, Flores L, et al
    Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1.
    Cancer Res. 2024 Sep 12. doi: 10.1158/0008-5472.CAN-24-1388.
    >> Share

    August 2024
  22. SONG H, Lu T, Han D, Zhang J, et al
    YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer.
    Cancer Res. 2024 Aug 13. doi: 10.1158/0008-5472.CAN-24-0932.
    >> Share

  23. NING S, Armstrong CM, Xing E, Leslie AR, et al
    LX1 Targets Androgen Receptor Variants and AKR1C3 to overcome Therapy Resistance in Advanced Prostate Cancer.
    Cancer Res. 2024 Aug 1. doi: 10.1158/0008-5472.CAN-24-0440.
    >> Share

    July 2024
  24. SHRESTHA R, Chesner LN, Zhang M, Zhou S, et al
    An Atlas of Accessible Chromatin in Advanced Prostate Cancer Reveals the Epigenetic Evolution during Tumor Progression.
    Cancer Res. 2024 Jul 11. doi: 10.1158/0008-5472.CAN-24-0890.
    >> Share

  25. YOO YA, Quan S, Yang W, Guo Q, et al
    Asparagine Dependency is a Targetable Metabolic Vulnerability in TP53-Altered Castration-Resistant Prostate Cancer.
    Cancer Res. 2024 Jul 3. doi: 10.1158/0008-5472.CAN-23-2910.
    >> Share

    June 2024
  26. ZHANG W, Maeser D, Lee A, Huang Y, et al
    Integration of Pan-Cancer Cell Line and Single-Cell Transcriptomic Profiles Enables Inference of Therapeutic Vulnerabilities in Heterogeneous Tumors.
    Cancer Res. 2024;84:2021-2033.
    >> Share

  27. LI W, Guo F, Zeng R, Liang H, et al
    CDK4/6 Alters TBK1 Phosphorylation to Inhibit the STING Signaling Pathway in Prostate Cancer.
    Cancer Res. 2024 Jun 11. doi: 10.1158/0008-5472.CAN-23-3704.
    >> Share

  28. BOUFAIED N, Chetta P, Hallal T, Cacciatore S, et al
    Obesogenic High-Fat Diet and MYC Cooperate to Promote Lactate Accumulation and Tumor Microenvironment Remodeling in Prostate Cancer.
    Cancer Res. 2024;84:1834-1855.
    >> Share

  29. FRIGO DE
    Diet and Tumor Genetics Conspire to Promote Prostate Cancer Metabolism and Shape the Tumor Microenvironment.
    Cancer Res. 2024;84:1742-1744.
    >> Share

  30. GALLAGHER K, Strobl MAR, Park DS, Spoendlin FC, et al
    Mathematical Model-Driven Deep Learning Enables Personalized Adaptive Therapy.
    Cancer Res. 2024;84:1929-1941.
    >> Share

    April 2024
  31. SHRESTHA RK, Nassar ZD, Hanson AR, Iggo R, et al
    ACSM1 and ACSM3 regulate fatty acid metabolism to support prostate cancer growth and constrain ferroptosis.
    Cancer Res. 2024 Apr 24. doi: 10.1158/0008-5472.CAN-23-1489.
    >> Share

  32. CUNNINGHAM M, Schiewer MJ
    PARP-ish: Gaps in Molecular Understanding and Clinical Trials Targeting PARP Exacerbate Racial Disparities in Prostate Cancer.
    Cancer Res. 2024 Apr 18. doi: 10.1158/0008-5472.CAN-23-3458.
    >> Share

  33. MURPHY S, Rahmy S, Gan D, Liu G, et al
    Ketogenic diet alters the epigenetic and immune landscape of prostate cancer to overcome resistance to immune checkpoint blockade therapy.
    Cancer Res. 2024 Apr 8. doi: 10.1158/0008-5472.CAN-23-2742.
    >> Share

    March 2024
  34. SHU F, Liu H, Chen X, Liu Y, et al
    m6A modification promotes EMT and metastasis of castration-resistant prostate cancer by upregulating NFIB.
    Cancer Res. 2024 Mar 27. doi: 10.1158/0008-5472.CAN-23-1954.
    >> Share

    January 2024
  35. ZHAO J, Xu N, Zhu S, Nie L, et al
    Genomic and Evolutionary Characterization of Concurrent Intraductal Carcinoma and Adenocarcinoma of the Prostate.
    Cancer Res. 2024;84:154-167.
    >> Share

    December 2023
  36. MISHRA R, Blinka S, Hsieh AC
    Citron Kinase Is a Druggable Target in Treatment-Resistant Prostate Cancer.
    Cancer Res. 2023;83:4008-4009.
    >> Share

  37. AWAD D, Cao PHA, Pulliam TL, Spradlin M, et al
    Adipose triglyceride lipase is a therapeutic target in advanced prostate cancer that promotes metabolic plasticity.
    Cancer Res. 2023 Dec 1. doi: 10.1158/0008-5472.CAN-23-0555.
    >> Share

    October 2023
  38. RAWAT C, Ben-Salem S, Singh N, Chauhan G, et al
    Prostate cancer progression relies on the mitotic kinase citron kinase.
    Cancer Res. 2023 Oct 6. doi: 10.1158/0008-5472.CAN-23-0883.
    >> Share

    September 2023
  39. LI Z, Ning K, Zhao D, Zhou Z, et al
    Targeting the metabolic enzyme PGAM2 overcomes enzalutamide resistance in castration-resistant prostate cancer by inhibiting BCL2 signaling.
    Cancer Res. 2023 Sep 7. doi: 10.1158/0008-5472.CAN-23-0308.
    >> Share

  40. NYQUIST MD, Coleman IM, Lucas JM, Li D, et al
    Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex.
    Cancer Res. 2023;83:2938-2951.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016